Gencer, D., & Hofheinz, R. (2013). Metastatic esophagogastric adenocarcinoma: Trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval. Journal of cancer research and clinical oncology, 139(2), .
Chicago-Zitierstil (17. Ausg.)Gencer, Deniz, und Ralf-Dieter Hofheinz. "Metastatic Esophagogastric Adenocarcinoma: Trends in First-line Treatment and Predictive Factors for the Implementation of HER2 Testing in Clinical Practice During the First Year After Trastuzumab Market Approval." Journal of Cancer Research and Clinical Oncology 139, no. 2 (2013).
MLA-Zitierstil (9. Ausg.)Gencer, Deniz, und Ralf-Dieter Hofheinz. "Metastatic Esophagogastric Adenocarcinoma: Trends in First-line Treatment and Predictive Factors for the Implementation of HER2 Testing in Clinical Practice During the First Year After Trastuzumab Market Approval." Journal of Cancer Research and Clinical Oncology, vol. 139, no. 2, 2013.